These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 883820)

  • 1. Metabolic fate of [14C]cefamandole, a parenteral cephalosporin antibiotic, in rats and dogs.
    Sullivan HR; Due SL; Kau DL; Quay JF; Miller WM
    Antimicrob Agents Chemother; 1977 Jul; 12(1):73-9. PubMed ID: 883820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic fate of [14C]-ceftizoxime, a parenteral cephalosporin antibiotic, in rats and dogs.
    Noda K; Suzuki A; Ohta H; Furukawa T; Noguchi H
    Arzneimittelforschung; 1980; 30(10):1665-9. PubMed ID: 6933993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals.
    Sullivan HR; Due SL; Kau DL; Quay JF; Miller W
    Antimicrob Agents Chemother; 1976 Oct; 10(4):630-8. PubMed ID: 984800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic fate of SCE-1365, a new broad-spectrum cephalosporin, after parenteral administration to rats and dogs.
    Tanayama S; Yoshida K; Adachi K; Kondo T
    Antimicrob Agents Chemother; 1980 Oct; 18(4):511-8. PubMed ID: 6934706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrolysis of cefamandole nafate to cefamandole in vivo.
    Wold JS; Joost RR; Black HR; Griffith RS
    J Infect Dis; 1978 May; 137 Suppl():S17-S24. PubMed ID: 650001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and pain study of cefamandole nafate.
    Foster TS; Shrewsbury RP; Coonrod JD
    J Clin Pharmacol; 1980; 20(8-9):526-33. PubMed ID: 7000857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicologic evaluation of cefamandole nafate in laboratory animals.
    Wold JS; Welles JS; Owen NV; Gibson WR; Morton DM
    J Infect Dis; 1978 May; 137 Suppl():S51-S59. PubMed ID: 650004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefazolin, a new semisynthetic cephalosporin antibiotic. 3. Absorption, excretion and tissue distribution in parenteral administration.
    Nishida M; Matsubara T; Murakawa T; Mine Y; Yokota Y; Goto S; Kuwahara S
    J Antibiot (Tokyo); 1970 Apr; 23(4):184-94. PubMed ID: 5423363
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic fate of SCE-129, a new antipseudomonal cephalosporin, after parenteral administration in rats and dogs.
    Tanayama S; Yoshida K; Kanai Y
    Antimicrob Agents Chemother; 1978 Jul; 14(1):137-43. PubMed ID: 686704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cefamandole nafate on the toxicity of tobramycin.
    Wold JS; Turnipseed SA; Broddle WD; Owen NV
    Antimicrob Agents Chemother; 1977 Oct; 12(4):465-9. PubMed ID: 921240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ceftizoxime in animals after parenteral dosing.
    Murakawa T; Sakamoto H; Fukada S; Nakamoto S; Hirose T; Itoh N; Nishida M
    Antimicrob Agents Chemother; 1980 Feb; 17(2):157-64. PubMed ID: 6770752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrolysis of cefamandole nafate in dialysis patients.
    Nielsen RL; Wolen R; Luft FC; Ozawa T
    Antimicrob Agents Chemother; 1979 Nov; 16(5):683-5. PubMed ID: 526012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.
    Matsui H; Yano K; Okuda T
    Antimicrob Agents Chemother; 1982 Aug; 22(2):213-7. PubMed ID: 6927282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic fate of [14C]SM-1652, a new antipseudomonal cephalosporin, after parenteral administration to rats.
    Imasaki H; Enjoji Y; Matsui H; Kawai R; Kawamura S; Okuda T
    Antimicrob Agents Chemother; 1983 Jul; 24(1):42-7. PubMed ID: 6625556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical versus systemic cephalosporin administration in elective biliary operations.
    Freischlag J; McGrattan M; Busuttil RW
    Surgery; 1984 Oct; 96(4):686-93. PubMed ID: 6435272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.
    Ratzan KR; Baker HB; Lauredo I
    Antimicrob Agents Chemother; 1978 Jun; 13(6):985-7. PubMed ID: 677864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftezole, a new cephalosporin C derivative II. Distribution and excretion in parenteral administration.
    Harada Y; Matsubara S; Kakimoto M; Noto T; Nehashi T
    J Antibiot (Tokyo); 1976 Oct; 29(10):1071-82. PubMed ID: 994326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.
    Ahern MJ; Finkelstein FO; Andriole VT
    Antimicrob Agents Chemother; 1976 Sep; 10(3):457-61. PubMed ID: 984787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental and clinical study of the biliary excretion of cefamandole (author's transl)].
    Brogard JM; Pinget M; Arnaud JP; Dorner M; Adloff M; Lavillaureix J
    Pathol Biol (Paris); 1981 Jan; 29(1):25-30. PubMed ID: 7010273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions.
    Bosso JA; Townsend RJ
    Am J Hosp Pharm; 1985 Oct; 42(10):2211-4. PubMed ID: 3864367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.